Is Addex Therapeutics Ltd (ADXN) a Buy, Sell, or Hold?
Addex Therapeutics Ltd
NASDAQ:ADXN
$5.8 USD
$0.09 (1.58%)
- Volume
- 5.99K
- Average Volume
- 3.94K
- Market Capitalization
- $4.18M
- P/E Ratio
- -0.71
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $12.05
- Year Low
- $5.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.97
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Timothy Mark Dyer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADXN |
| CUSIP | 00654J206 |
| CIK | 0001574232 |
| Web | https://www.addextherapeutics.com |
| Phone | 41 22 884 1555 |
| Currency | USD |
| Employees | 3 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.97 |
| Quick Ratio | 0.97 |
| Cash Ratio | 0.77 |
Sales & Book Value
| Annual Sales | $29972 |
| Price / Sales | 66.78 |
| Cash Flow | -0.01 |
| Price / Cash Flow | -2.56 |
| Price / Book | 2.05 |
Price Target and Rating
| Average Stock Price Forecast | $30.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -80.67% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.88 |
| Trailing P/E Ratio | -0.71 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-6.73M |
| Net Margin | -7775.20% |
| Pretax Margin | -7901.66% |
| Return on Equity | -131.35% |
| Return on Assets | -146.41% |
Financials Score
| AltmanZ Score | -109.98 |
| Piotroski Score | 1.00 |
| Working Capital | -32.56K |
| Total Assets | 4.76M |
| Ebit | -7.08M |
| Market Cap | 3.32M |
| Total Liabilities | 1.47M |
Poll Results
About Addex Therapeutics Ltd (NASDAQ:ADXN) Stock
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and ... The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
2026-06-25 13:12:13
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-06-25 01:00:00
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.
2026-06-22 01:00:00
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on June 25, 2026.
Addex Convenes Annual General Meeting 2026
2026-06-05 01:00:00
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
2026-04-30 17:11:34
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-04-30 01:00:00
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders Cash position of CHF 1.6 million at December 31, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.
2026-04-29 01:00:00
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.
2026-04-21 01:00:00
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model.
Frequently Asked Questions
-
What is the current Addex Therapeutics Ltd (ADXN) stock price?
-
Addex Therapeutics Ltd(NASDAQ:ADXN) stock price is $5.8 in the last trading session. During the trading session, ADXN stock reached the peak price of $12.05 while $5.41 was the lowest point it dropped to. The percentage change in ADXN stock occurred in the recent session was 1.58% while the dollar amount for the price change in ADXN stock was $0.09.
-
ADXN's industry and sector of operation?
-
The NASDAQ listed ADXN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADXN?
-
Mikhail Kalinichev | Head of Translational Science
Roger G. Mills | Chief Medical Officer & Director
Lénaic Teyssédou | Head of Finance
Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director
| -
How many employees does ADXN have?
-
Number of ADXN employees currently stands at 3. ADXN operates from Chemin des Mines, 9, Geneva, GE 1202, CH.
-
Link for ADXN official website?
-
Official Website of ADXN is: https://www.addextherapeutics.com
-
How do I contact ADXN?
-
ADXN could be contacted at phone #41 22 884 1555 and can also be accessed through its website. ADXN operates from Chemin des Mines, 9, Geneva, GE 1202, CH.
-
How many shares of ADXN are traded daily?
-
The average number of ADXN shares traded daily for last 3 months was 3.94K.
-
What is the market cap of ADXN currently?
-
The market value of ADXN currently stands at $4.18M with its latest stock price at $5.8